- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.
EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
EP: 6.Future Directions in the Management of Multiple Myeloma
Video content above is prompted by the following questions:
1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving prophylactic tocilizumab for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study.
a. What is the background for using tocilizumab prior to administration of bispecific antibodies?
b. What methodology was used to study this cohort of patients?
c. What results were presented?
i. N=24
ii. Median follow-up: 8.1 months
iii. CRS occurred in 6 pts (25%; 2 grade 1, 4 grade 2, no grade ≥3)
iv. Reduced incidence of CRS with teclistamab vs overall MajesTEC-1 population
2. Please provide your key takeaways from this study. What are the implications of favorable safety results with the use of prophylactic tocilizumab?
3. In what patients are you currently using prophylactic tocilizumab? Who should be considered for it?
Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone
August 21st 2025Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.
Read More
On the Path to Greater Precision in Treating Multiple Myeloma
August 18th 2025Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.
Read More
How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community
August 12th 2025International Myeloma Foundation Chief Medical Office Joseph Mikhael, MD, shares how the M-Power initiative is addressing disparities through community engagement, education, and improved clinical trial access.
Read More
